文献速递神经免疫神经重症与神经感染

托珠单抗在儿童重症中枢神经系统炎症中的作用

Role of Tocilizumab in Severe CNS Inflammatory Presentations in Children.
PubMed 文献 · Neurology · 2026-04-07

脑脊液IL-6升高的5例中3例对托珠单抗有反应。

要点

  • 静脉托珠单抗可能改善部分儿童急性重症中枢神经系统炎症的临床结局
  • 72小时内可观察到改善,包括快速降低颅内压和视神经炎/脊髓炎恢复
  • 脑脊液IL-6升高而血清IL-6正常的患儿中部分对托珠单抗有反应

核心结论

  • 托珠单抗可能对特定神经炎症性疾病有潜在获益,但需临床试验确认疗效并指导使用。

主要发现

  • 结局包括快速降低颅内压、复发性视神经炎和脊髓炎恢复以及RANBP2相关急性坏死性脑病改善。
  • 未观察到急性不良反应,1例尽管接受免疫治疗仍死亡。
  • 脑脊液细胞因子检测显示5例IL-6升高而血清IL-6浓度正常,其中3例对托珠单抗有反应。

关键数值与推荐

  • 主要评估指标为托珠单抗给药后72小时内的反应。
  • 研究提供IV级证据表明托珠单抗改善儿童急性重症中枢神经系统炎症事件的临床结局。

临床怎么用

  • 在特定儿童急性重症中枢神经系统炎症中可考虑静脉托珠单抗,尤其脑脊液IL-6升高而血清IL-6正常者可能部分获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Anti-interleukin 6 receptor (anti-IL6R) therapies have been proven to reduce relapse rates in patients with neuromyelitis optica spectrum disorder and are under investigation in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). One anti-IL6R therapy, tocilizumab (TCZ), has been reported as a treatment option in cases of life-threatening MOGAD attacks. The aim of this study was to further evaluate the safety and effectiveness of IV-TCZ for acute and severe CNS inflammatory events in children. METHODS: This retrospective study reviewed medical records of children younger than 18 years treated with IV-TCZ for acute-severe CNS inflammation at the Children's Hospital of Philadelphia between 2022 and 2025, excluding those with new-onset refractory status epilepticus without evidence of CNS inflammation. Clinical features, imaging, serum and CSF profiles, treatments, and outcomes were assessed, with primary evaluation of TCZ response within 72 hours postadministration. RESULTS: Eleven patients were included, of whom 8 demonstrated clinical improvement within 72 hours of IV-TCZ administration. Outcomes included rapid intracranial pressure reduction, recovery in relapsing optic neuritis and myelitis, and improvement in RANBP2-related acute necrotizing encephalopathy. No acute adverse effects were observed. One patient died despite immunotherapy. CSF cytokine panels showed elevated IL-6 in 5 patients, with normal serum IL-6 concentrations. Three of the 5 showed a response to TCZ. DISCUSSION: TCZ may offer potential benefit in select neuroinflammatory conditions, although clinical trials are needed to confirm its efficacy and guide use in such scenarios. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that TCZ improves clinical outcomes in children with acute-severe CNS inflammatory events.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Marefi A, Grasso EA, McLendon LA, et al. Role of Tocilizumab in Severe CNS Inflammatory Presentations in Children. Neurology. 2026. PMID: 41945878. doi:10.1212/WNL.0000000000214926

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。